Why is the use of neuromuscular blocking agents (paralysis) not recommended when inserting a laryngeal mask airway (LMA)? | Rounds Why is the use of neuromuscular blocking agents (paralysis) not recommended when inserting a laryngeal mask airway (LMA)? | Rounds
Loading...

Why is the use of neuromuscular blocking agents (paralysis) not recommended when inserting a laryngeal mask airway (LMA)?

Medical Advisory Board
All articles are reviewed for accuracy by our Medical Advisory Board.

Educational purpose only · Not a substitute for professional judgment or the full text of guidelines and labels.

Article Review Status
Submitted
Under Review
Approved

Last updated: July 14, 2026 · View editorial policy

Routine Neuromuscular Blocking Agent Avoidance for Laryngeal Mask Airway Insertion

Routine neuromuscular blocking agents are not recommended for laryngeal mask airway (LMA) insertion. This recommendation is supported by the SEDAR perioperative neuromuscular blockade guidance, which specifically advises against routine NMBA use for supraglottic airway device insertion and reserves NMBA use for airway obstruction or failed ventilation scenarios. [1]

Mechanistic Rationale for Avoidance

LMA insertion primarily depends on achieving adequate depth of anesthesia and suppressing airway reflexes, rather than head and neck muscle relaxation typical of tracheal intubation requirements. [1]

NMBA exposure increases the probability of peri- and postoperative respiratory risk related to residual neuromuscular blockade, including impaired upper-airway dilator muscle function. [2]

Evidence Basis for “No Routine NMBA” Approach

An SEDAR recommendation states that neuromuscular blocking agents should not be used for routine insertion of supraglottic airway devices and should only be used when obstruction occurs or when endotracheal intubation through the device is required. [1]

Clinical Selection Algorithm for When NMBA May Be Used

NMBA use is recommended only when supraglottic ventilation or subsequent airway management requires it, including:

  • Airway obstruction after supraglottic device placement. [1]
  • Endotracheal intubation through the supraglottic device. [1]

NMBA use is not indicated for routine LMA insertion when supraglottic placement conditions can be achieved with anesthetic technique. [1]

Initiation and Target Conditions for Routine LMA Insertion

Routine LMA insertion should be performed without NMBA when adequate conditions are met using anesthetic depth strategies consistent with standard supraglottic airway practice. [1]

Key Nuances and Risk-Tradeoffs

Residual neuromuscular blockade is associated with increased risk of postoperative hypoxemia or respiratory failure in relevant populations, which supports limiting NMBA exposure when not required for the insertion task. [2]

Difficulty of LMA placement has been associated in observational data with omission of NMBA in some settings, but this association does not override the guideline recommendation against routine NMBA use for supraglottic device insertion. [3]

Common Pitfalls to Avoid

Routine NMBA administration for LMA insertion should be avoided because it adds neuromuscular monitoring and reversal considerations without addressing the primary determinants of successful supraglottic placement. [1]

Avoidance of NMBA for supraglottic insertion does not eliminate the need for readiness to escalate airway management when ventilation through the device becomes inadequate. [1]

Practical Approach to Failed or Difficult LMA Situations

Escalation strategies for inadequate ventilation or obstruction should proceed with reassessment of airway management rather than defaulting to NMBA for routine insertion. [1]

NMBA use should be reserved for the guideline-defined situations where obstruction occurs or when endotracheal intubation through the device is required. [1]

Related Questions